Source: European Medicines Agency (EU) Revision Year: 2025 Publisher: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
Spravato 28 mg nasal spray, solution.
| Pharmaceutical Form |
|---|
|
Nasal spray, solution. Clear, colourless, aqueous solution. |
Each nasal spray device contains esketamine hydrochloride corresponding to 28 mg esketamine.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Esketamine is the S-enantiomer of racemic ketamine. It is a non-selective, non-competitive, antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. Through NMDA receptor antagonism, esketamine produces a transient increase in glutamate release leading to increases in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) stimulation and subsequently to increases in neurotrophic signalling which may contribute to the restoration of synaptic function in these brain regions involved with the regulation of mood and emotional behaviour. Restoration of dopaminergic neurotransmission in brain regions involved in the reward and motivation, and decreased stimulation of brain regions involved in anhedonia, may contribute to the rapid response. |
| List of Excipients |
|---|
|
Citric acid monohydrate |
Type-I glass vial with a chlorobutyl rubber stopper. The filled and stoppered vial is assembled into a manually-activated nasal spray device. The device dispenses two sprays.
Within each pack, each device is individually packaged in a sealed blister.
Pack sizes of 1, 2, 3, or 6 nasal spray devices and in multipacks containing 12 (4 packs of 3) or 24 (8 packs of 3) nasal spray devices.
Not all pack sizes may be marketed.
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
EU/1/19/1410/001 (1 spray container)
EU/1/19/1410/002 (2 spray containers)
EU/1/19/1410/003 (3 spray containers)
EU/1/19/1410/004 (6 spray containers)
EU/1/19/1410/005 (24 spray containers)
EU/1/19/1410/006 (12 spray containers)
Date of first authorisation: 18 December 2019
Date of last renewal: 22 August 2024
| Drug | Countries | |
|---|---|---|
| SPRAVATO | Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.